Physician profile
Robert G Miller
NPI 1639142524
$11,012.05
in general payments reported to CMS, 2019-2025
32 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $1,739 · 2021: $1,318 · 2022: $709 · 2023: $1,758 · 2024: $1,771 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,148 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.26 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,924.54 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,772.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,337.86 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,325.99 | 2019-2025 | |
| Amarin Pharma, INC. | $643.08 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.06 | 2019-2024 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $441.26 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $420.40 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $382.06 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $372.18 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $312.45 | 2019-2023 | Delstrigo, Dificid, Pifeltro |
| Corcept Therapeutics | $269.62 | 2024-2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $210.33 | 2023 | Quviviq |
| Amgen INC. | $203.42 | 2019-2021 | |
| Allergan, INC. | $180.07 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.23 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $94.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $52.55 | 2019-2020 | |
| Eisai INC. | $51.59 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $49.05 | 2021-2022 | |
| Daiichi Sankyo INC. | $40.72 | 2020-2021 | |
| Antares Pharma, INC. | $27.55 | 2024 | Xyosted |
| Axsome Therapeutics, INC. | $25.69 | 2023 | Auvelity |
| Boston Scientific Corporation | $24.86 | 2025 | Watchman Flx |
| Arbor Pharmaceuticals, INC. | $24.06 | 2019 | |
| Kerecis Limited | $21.26 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Clarus Therapeutics INC. | $19.24 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.57 | 2021 | |
| Bausch Health US, LLC | $17.76 | 2020 | |
| Exact Sciences Corporation | $15.42 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $15.39 | 2019 | |
| Tris Pharma INC | $15.09 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.